Business
Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single–patient–use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).
About this update from Cipla Ltd
[{"type":"text","content":"Partner Orbicular receives ANDA approval from USFDA","length":51,"tagName":"p"},{"type":"text","content":"MUMBAI, India and WARREN, N.J., Feb. 27, 2026 /PRNewswire/ -- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single–patient–use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).","length":368,"tagName":"p"},{"type":"image","alt":"Cipla Logo (PRNewsfoto/Cipla USA Inc.)","displaySize":"","headline":null,"caption":"Cipla Logo (PRNewsfoto/Cipla USA Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":160,"url":"https://media.zenfs.com/en/prnewswire.com/2ec3a8b4449867b7a94dba950259b48f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i4HA491X1TqSo1C3HkSUqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ec3a8b4449867b7a94dba950259b48f","width":400,"height":160}},"href":"https://mma.prnewswire.com/media/2922246/5828046/Cipla_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This milestone builds on the recent Abbreviated New Drug Approval (ANDA) by United States Food & Drugs Administration (USFDA) obtained by its partner, Orbicular, for Liraglutide Injection(generic Saxenda®). Cipla will lead the product's marketing and distribution, enabling broad access and reliable availability for patients. The company is set to commence the launch on an immediate basis.","length":404,"tagName":"p"},{"type":"text","content":"Liraglutide Injection is a complex injectable peptide delivered through a multidose injector pen drug–device combination. It is indicated as an adjunct to a reduced–calorie diet and increased physical activity for chronic weight management in patients meeting defined clinical criteria.","length":286,"tagName":"p"},{"type":"text","content":"Commenting on the launch, Achin Gupta, Global CEO & MD Designate, Cipla, said, "This development represents a key milestone in our peptide portfolio and strengthens our differentiated U.S. offering. We remain focused on expanding access to high–quality, affordable medicines at scale, supported by disciplined execution and collaboration."","length":358,"tagN...